Oramed Pharmaceuticals
ORMP
25 hedge funds and large institutions have $3.83M invested in Oramed Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 6 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4.76% less ownership
Funds ownership: 10.94% → 6.18% (-4.8%)
11% less funds holding
Funds holding: 28 → 25 (-3)
33% less capital invested
Capital invested by funds: $5.7M → $3.83M (-$1.86M)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$154K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$34.8K |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$33.1K |
| 4 |
CAM
Close Asset Management
London,
United Kingdom
|
+$24.1K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$12.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.63M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$832K |
| 3 |
SFFS
Stonehage Fleming Financial Services
St. Helier,
Jersey
|
-$231K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$55K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$51K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
26
Armistice Capital
New York
| – | -$1.63M | -542,944 | Closed |
|
|
SFFS
27
Stonehage Fleming Financial Services
St. Helier,
Jersey
| – | -$231K | -76,909 | Closed |
|
|
28
Northern Trust
Chicago,
Illinois
| – | -$55K | -18,269 | Closed |
|
|
29
Group One Trading
Chicago,
Illinois
| – | -$51K | -16,900 | Closed |
|
30
Simplex Trading
Chicago,
Illinois
| – | -$3K | -1,035 | Closed |
|
|
FHA
31
Flagship Harbor Advisors
Boston,
Massachusetts
| – | -$2K | -700 | Closed |
|
ORMP Hedge Fund Activity: Q1 2019 in Review
25 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q1 2019, worth a combined $3.83M — down 33% from $5.7M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ORMP and 3 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, adding an estimated $154K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.63M sold.
- 25 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q1 2019, down from 28 in Q4 2018.
- Funds reported $3.83M of Oramed Pharmaceuticals stock for Q1 2019, down 33% quarter-over-quarter.
- 3 funds opened new Oramed Pharmaceuticals positions in Q1 2019 and 6 closed out, a net change of -3 holders.
- The largest Oramed Pharmaceuticals buyer in Q1 2019 was Renaissance Technologies, an estimated $154K added.
- The largest Oramed Pharmaceuticals seller in Q1 2019 was Armistice Capital, an estimated $1.63M sold.
Based on aggregated 13F filings for Q1 2019.